# EDGAR Filing Document

**Accession Number:** 0001313938
**File Stem:** 0000000000-23-001770
**Filing Date:** 2023-2
**Character Count:** 4236
**Document Hash:** e5cbae7e0d585c53930f67b22dd9e562
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001770.hdr.sgml**: 20230412

**ACCESSION NUMBER**: 0000000000-23-001770

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230222

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sibannac, Inc.
- **CENTRAL INDEX KEY:** 0001313938
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 330903494
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 2122 E. HIGHLAND AVENUE, SUITE 425
- **CITY:** PHOENIX
- **STATE:** AZ
- **ZIP:** 85016
- **BUSINESS PHONE:** 480-498-8300

**MAIL ADDRESS:**
- **STREET 1:** 2122 E. HIGHLAND AVENUE, SUITE 425
- **CITY:** PHOENIX
- **STATE:** AZ
- **ZIP:** 85016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sibannic, Inc.
- **DATE OF NAME CHANGE:** 20150310

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Naprodis, Inc.
- **DATE OF NAME CHANGE:** 20050110
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001683168-23-001035

## Text-Extract

```

United States securities and exchange commission logo

                             February 22, 2023

       David Mersky
       Chief Executive Officer
       Sibannac, Inc.
       9535 E. Doubletree Ranch Rd., Ste 120
       Scottsdale, AZ 85258

                                                        Re: Sibannac, Inc.
                                                            Offering Statement
on Form 1-A
                                                            Filed February 17,
2023
                                                            File No. 024-12159

       Dear David Mersky:

                                                        This is to advise you
that we do not intend to review your offering statement.

               We will consider qualifying your offering statement at your
request. In connection with
       your request, please confirm in writing that at least one state has
advised you that it is prepared
       to qualify or register your offering. If a participant in your offering
is required to clear its
       compensation arrangements with FINRA, please have FINRA advise us that
it has no objections
       to the compensation arrangements prior to qualification.

               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.

                                                        Please contact Tyler
Howes at 202-551-3370 with any questions.

                             Sincerely,

                             Division of Corporation Finance

                             Office of Life Sciences
       cc:                                              Carl Ranno, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 22, 2023

David Mersky
Chief Executive Officer
Sibannac, Inc.
9535 E. Doubletree Ranch Rd., Ste 120
Scottsdale, AZ 85258

**Re: Sibannac, Inc.**
**Offering Statement on Form 1-A**
**Filed February 17, 2023**
**File No. 024-12159**

Dear David Mersky:

This is to advise you that we do not intend to review your offering statement.

We will consider qualifying your offering statement at your request. In connection with your request, please confirm in writing that at least one state has advised you that it is prepared to qualify or register your offering. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Carl Ranno, Esq.